Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer

Medical Oncology

Volumn 34, Issue 10, 2017, Pages

  Katz, Heather ^a   Wassie, Emnet ^a   Alsharedi, Mohamed ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Checkpoint inhibitors; Immune therapy; Urothelial bladder cancer

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; HUMAN; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; URINARY BLADDER NEOPLASMS;

EID: 85028774392     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-017-1029-8     Document Type: Review

References (25)

1. Finn O. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(Supplement 8):viii6–9. doi:10.1093/annonc/mds256.
2. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
3. Rosenberg J, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
4. Massard C, Gordon M, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–25.
5. Heery C, O’Sullivan-Coyne G, Madan R, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–98.
6. Apolo A, Infante J, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117–24.
7. Patel M, Ellerton J, Infante J, et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial. J Clin Oncol. 2017; 35(supplement 6S), abstract 330.
8. Sharma P, Callahan M, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (Check-Mate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–8.
9. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Check-Mate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22.
10. Plimack E, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212–20.
11. Balar A, Castellano D, O’Donnell P, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population. J Clin Oncol. 2017; 35(supplement 6S), abstract 284.
12. Bellmunt J, de Wit R, Vaughn D, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.
13. Carthon B, Wolchok J, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861–71.
14. Prescott S, Jackson A, Hawkyard S, et al. Mechanisms of action of intravesical bacille Calmette–Guérin: local immune mechanisms. Clin Infect Dis. 2000;31(Suppl 3):S91.
15. Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.
16. Sternberg C, de Mulder P, Schornagel J, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.
17. Dash A, Pettus J, Herr H, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471–7.
18. Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189–99 (discussion 199-201).
19. Siegel R, Miller K, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
20. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.
21. Gupta S, Gill D, Poole A, Agarwal N. Systemic immunotherapy for urothelial cancer: current trends and future direction. Cancer. 2017;9(15):1–14.
22. Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
23. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–9.
24. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.
25. Zilchi C, Tucci M, Leone G, et al. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. BioMed Res Int. 2017; 2017, Article ID 5618174. doi:10.1155/2017/5618174.